Key terms

About ANNX

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANNX news

Apr 08 6:40am ET Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO) Apr 01 6:38am ET Annexon added to ‘Q2 Tactical Ideas List’ at Wells Fargo Apr 01 6:03am ET Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM) Mar 31 10:51am ET Annexon price target raised to $13 from $11 at JPMorgan Mar 28 7:57am ET Annexon price target raised to $10 from $7 at BofA Mar 28 4:57am ET Anticipating Growth: Positive Outlook for Annexon Biosciences Amid Upcoming Clinical Trials and New Data Readouts Mar 27 6:16am ET Annexon price target raised to $12 from $11 at Wells Fargo Mar 26 10:25pm ET Annexon Biosciences (ANNX) Receives a Buy from TD Cowen Mar 26 5:12pm ET Annexon files $400M mixed securities shelf Mar 26 4:09pm ET Annexon reports Q4 EPS (36c), consensus (44c) Mar 25 2:05pm ET Annexon options imply 24.7% move in share price post-earnings Mar 25 1:15pm ET Annexon participates in a conference call with JPMorgan Mar 25 11:44am ET Annexon participates in a conference call with JPMorgan Mar 04 5:44pm ET Annexon Biosciences Hosts Virtual R&D Day Event Mar 01 4:59am ET Annexon upgraded to Overweight from Neutral at JPMorgan Mar 01 4:31am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), GoodRx Holdings (GDRX) and Annexon Biosciences (ANNX)

No recent press releases are available for ANNX

ANNX Financials

1-year income & revenue

Key terms

ANNX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANNX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms